Patents by Inventor Jaakko Lappalainen
Jaakko Lappalainen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250082651Abstract: The disclosure provides a method of treating a mammal having a genetic epileptic disorder, comprising chronically administering a pharmaceutically acceptable pregnenolone neurosteroid to a mammal having a genetic epileptic disorder in an amount effective to reduce the seizure frequency in the mammal. In certain preferred embodiments, the mammal is a human patient who has a CDKL5 genetic mutation. In certain preferred embodiments, the patient has a low endogenous level of a neurosteroid(s). In certain preferred embodiments, the pregnenolone neurosteroid is ganaxolone.Type: ApplicationFiled: March 21, 2024Publication date: March 13, 2025Inventors: Lorianne Masuoka, Jaakko Lappalainen
-
Publication number: 20220249515Abstract: The disclosure provides a method of treating a mammal having a genetic epileptic disorder, comprising chronically administering a pharmaceutically acceptable pregnenolone neurosteroid to a mammal having a genetic epileptic disorder in an amount effective to reduce the seizure frequency in the mammal. In certain preferred embodiments, the mammal is a human patient who has a CDKL5 genetic mutation. In certain preferred embodiments, the patient has a low endogenous level of a neurosteroid(s). In certain preferred embodiments, the pregnenolone neurosteroid is ganaxolone.Type: ApplicationFiled: March 24, 2022Publication date: August 11, 2022Inventors: Lorianne K. Masuoka, Jaakko Lappalainen
-
Patent number: 11266662Abstract: Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and at a rate sufficient to alleviate at least one symptom of postpartum depression in the female.Type: GrantFiled: December 6, 2019Date of Patent: March 8, 2022Assignee: Marinus Pharmaceuticals, Inc.Inventors: Alex Aimetti, Christopher Cashman, Lorianne Masuoka, Jaakko Lappalainen
-
Patent number: 11000531Abstract: The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether ?-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurosteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.Type: GrantFiled: March 25, 2020Date of Patent: May 11, 2021Assignee: Marinus Pharmaceuticals, Inc.Inventors: Christopher Cashman, Jaakko Lappalainen, David A. Czekai
-
Publication number: 20200289530Abstract: The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether ?-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurossteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.Type: ApplicationFiled: March 25, 2020Publication date: September 17, 2020Inventors: Christopher Cashman, Jaakko Lappalainen, David A. Czekai
-
Publication number: 20200179403Abstract: Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and at a rate sufficient to alleviate at least one symptom of postpartum depression in the female.Type: ApplicationFiled: December 6, 2019Publication date: June 11, 2020Applicant: Marinus Pharmaceuticals, Inc.Inventors: Alex Aimetti, Christopher Cashman, Lorianne Masuoka, Jaakko Lappalainen
-
Patent number: 10639317Abstract: The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether ?-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurosteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.Type: GrantFiled: October 3, 2018Date of Patent: May 5, 2020Assignee: MARINUS PHARMACEUTICALS INC.Inventors: Christopher Cashman, Jaakko Lappalainen, David A Czekai
-
Patent number: 10391105Abstract: The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether ?-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurossteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.Type: GrantFiled: September 11, 2017Date of Patent: August 27, 2019Assignee: MARINUS PHARMACEUTICALS INC.Inventors: Christopher Cashman, Jaakko Lappalainen, David A Czekai
-
Publication number: 20190167698Abstract: The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether ?-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurosteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.Type: ApplicationFiled: October 3, 2018Publication date: June 6, 2019Inventors: Christopher Cashman, Jaakko Lappalainen, David A. Czekai
-
Publication number: 20190160078Abstract: The disclosure provides a method of treating a mammal having a genetic epileptic disorder, comprising chronically administering a pharmaceutically acceptable pregnenolone neurosteroid to a mammal having a genetic epileptic disorder in an amount effective to reduce the seizure frequency in the mammal. In certain preferred embodiments, the mammal is a human patient who has a CDKL5 genetic mutation. In certain preferred embodiments, the patient has a low endogenous level of a neurosteroid(s). In certain preferred embodiments, the pregnenolone neurosteroid is ganaxolone.Type: ApplicationFiled: November 9, 2018Publication date: May 30, 2019Applicant: Marinus Pharmaceuticals, Inc.Inventors: Lorianne K. Masuoka, Jaakko Lappalainen
-
Publication number: 20180071315Abstract: The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether ?-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurossteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.Type: ApplicationFiled: September 11, 2017Publication date: March 15, 2018Inventors: Christopher Cashman, Jaakko Lappalainen, David A. Czekai
-
Patent number: 5654139Abstract: We describe identification of a non-conservative amino acid substitution in the 5-HT.sub.2C receptor gene. The variant was found using single strand conformational polymorphism (SSCP) analysis. By typing this polymorphism in CEPH families, the gene was genetically mapped on the long arm of the X chromosome. Since this polymorphism was not detectable as a conventional RFLP, we also developed a PCR-RFLP based method which allows rapid genotyping in populations and families.Type: GrantFiled: September 21, 1994Date of Patent: August 5, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jaakko Lappalainen, Markku Linnoila, David Goldman